Does the media refer more to ANVS or CORT?

In the previous week, Corcept Therapeutics had 29 more articles in the media than Annovis Bio. MarketBeat recorded 30 mentions for Corcept Therapeutics and 1 mentions for Annovis Bio. Corcept Therapeutics' average media sentiment score of 0.79 beat Annovis Bio's score of 0.00 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corcept Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to JAZZ or CORT?

In the previous week, Corcept Therapeutics had 5 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 30 mentions for Corcept Therapeutics and 25 mentions for Jazz Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 0.79 beat Jazz Pharmaceuticals' score of 0.57 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Corcept Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor SUPN or CORT?

In the previous week, Corcept Therapeutics had 28 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 30 mentions for Corcept Therapeutics and 2 mentions for Supernus Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 0.79 beat Supernus Pharmaceuticals' score of 0.71 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to NKTR or CORT?

In the previous week, Corcept Therapeutics had 14 more articles in the media than Nektar Therapeutics. MarketBeat recorded 30 mentions for Corcept Therapeutics and 16 mentions for Nektar Therapeutics. Corcept Therapeutics' average media sentiment score of 0.79 beat Nektar Therapeutics' score of 0.02 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corcept Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to CORT or PRGO?

In the previous week, Corcept Therapeutics had 16 more articles in the media than Perrigo. MarketBeat recorded 30 mentions for Corcept Therapeutics and 14 mentions for Perrigo. Corcept Therapeutics' average media sentiment score of 0.79 beat Perrigo's score of 0.01 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Perrigo 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Corcept Therapeutics (CORT) Competitors

$72.65 +1.45 (+2.04%)

Closing price 04:00 PM Eastern

Extended Trading

$72.67 +0.02 (+0.03%)

As of 05:17 PM Eastern

Compare

CORT vs. ANVS, JAZZ, SUPN, NKTR, and PRGO

Should you buy Corcept Therapeutics stock or one of its competitors? MarketBeat compares Corcept Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Corcept Therapeutics include Annovis Bio (ANVS), Jazz Pharmaceuticals (JAZZ), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), and Perrigo (PRGO). These companies are all part of the "medical" sector.

How does Corcept Therapeutics compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

In the previous week, Corcept Therapeutics had 29 more articles in the media than Annovis Bio. MarketBeat recorded 30 mentions for Corcept Therapeutics and 1 mentions for Annovis Bio. Corcept Therapeutics' average media sentiment score of 0.79 beat Annovis Bio's score of 0.00 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corcept Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Corcept Therapeutics has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
Corcept Therapeutics	$761.41M	10.24	$99.65M	$0.35	207.57

Annovis Bio presently has a consensus target price of $13.50, indicating a potential upside of 626.98%. Corcept Therapeutics has a consensus target price of $88.83, indicating a potential upside of 22.28%. Given Annovis Bio's higher probable upside, equities analysts clearly believe Annovis Bio is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Corcept Therapeutics has a net margin of 6.14% compared to Annovis Bio's net margin of 0.00%. Corcept Therapeutics' return on equity of 7.40% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
Corcept Therapeutics	6.14%	7.40%	5.76%

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Annovis Bio has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

Summary

Corcept Therapeutics beats Annovis Bio on 13 of the 16 factors compared between the two stocks.

How does Corcept Therapeutics compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Corcept Therapeutics has a net margin of 6.14% compared to Jazz Pharmaceuticals' net margin of 0.66%. Jazz Pharmaceuticals' return on equity of 14.56% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	0.66%	14.56%	5.25%
Corcept Therapeutics	6.14%	7.40%	5.76%

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 4.3% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Jazz Pharmaceuticals presently has a consensus target price of $242.65, suggesting a potential upside of 5.06%. Corcept Therapeutics has a consensus target price of $88.83, suggesting a potential upside of 22.28%. Given Corcept Therapeutics' higher probable upside, analysts clearly believe Corcept Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Corcept Therapeutics had 5 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 30 mentions for Corcept Therapeutics and 25 mentions for Jazz Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 0.79 beat Jazz Pharmaceuticals' score of 0.57 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Corcept Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Corcept Therapeutics has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.44B	3.26	-$356.15M	-$0.02	N/A
Corcept Therapeutics	$761.41M	10.24	$99.65M	$0.35	207.57

Jazz Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market.

Summary

Corcept Therapeutics beats Jazz Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Corcept Therapeutics compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

In the previous week, Corcept Therapeutics had 28 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 30 mentions for Corcept Therapeutics and 2 mentions for Supernus Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 0.79 beat Supernus Pharmaceuticals' score of 0.71 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

93.6% of Corcept Therapeutics shares are held by institutional investors. 8.8% of Supernus Pharmaceuticals shares are held by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Corcept Therapeutics has a net margin of 6.14% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%
Corcept Therapeutics	6.14%	7.40%	5.76%

Supernus Pharmaceuticals has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market.

Supernus Pharmaceuticals currently has a consensus price target of $62.17, suggesting a potential upside of 41.16%. Corcept Therapeutics has a consensus price target of $88.83, suggesting a potential upside of 22.28%. Given Supernus Pharmaceuticals' higher probable upside, equities analysts clearly believe Supernus Pharmaceuticals is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Corcept Therapeutics has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.56	-$38.55M	-$0.51	N/A
Corcept Therapeutics	$761.41M	10.24	$99.65M	$0.35	207.57

Summary

Corcept Therapeutics beats Supernus Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Corcept Therapeutics compare to Nektar Therapeutics?

Nektar Therapeutics (NASDAQ:NKTR) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Corcept Therapeutics has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.63M	35.97	-$164.08M	-$8.42	N/A
Corcept Therapeutics	$761.41M	10.24	$99.65M	$0.35	207.57

Corcept Therapeutics has a net margin of 6.14% compared to Nektar Therapeutics' net margin of -284.18%. Corcept Therapeutics' return on equity of 7.40% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-284.18%	-85.40%	-39.99%
Corcept Therapeutics	6.14%	7.40%	5.76%

Nektar Therapeutics presently has a consensus price target of $149.63, indicating a potential upside of 152.62%. Corcept Therapeutics has a consensus price target of $88.83, indicating a potential upside of 22.28%. Given Nektar Therapeutics' higher probable upside, research analysts clearly believe Nektar Therapeutics is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 2.5% of Nektar Therapeutics shares are owned by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Nektar Therapeutics has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

In the previous week, Corcept Therapeutics had 14 more articles in the media than Nektar Therapeutics. MarketBeat recorded 30 mentions for Corcept Therapeutics and 16 mentions for Nektar Therapeutics. Corcept Therapeutics' average media sentiment score of 0.79 beat Nektar Therapeutics' score of 0.02 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corcept Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Corcept Therapeutics beats Nektar Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Corcept Therapeutics compare to Perrigo?

Corcept Therapeutics (NASDAQ:CORT) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

Corcept Therapeutics has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, Perrigo has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market.

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by company insiders. Comparatively, 0.4% of Perrigo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Corcept Therapeutics has a net margin of 6.14% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.14%	7.40%	5.76%
Perrigo	-43.50%	9.96%	3.90%

Corcept Therapeutics has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	10.24	$99.65M	$0.35	207.57
Perrigo	$4.25B	0.34	-$1.43B	-$13.10	N/A

Corcept Therapeutics presently has a consensus target price of $88.83, suggesting a potential upside of 22.28%. Perrigo has a consensus target price of $19.33, suggesting a potential upside of 85.27%. Given Perrigo's higher probable upside, analysts clearly believe Perrigo is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Corcept Therapeutics had 16 more articles in the media than Perrigo. MarketBeat recorded 30 mentions for Corcept Therapeutics and 14 mentions for Perrigo. Corcept Therapeutics' average media sentiment score of 0.79 beat Perrigo's score of 0.01 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Perrigo	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Corcept Therapeutics beats Perrigo on 12 of the 17 factors compared between the two stocks.

Get Corcept Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CORT vs. The Competition

Export

Metric	Corcept Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.80B	$2.91B	$6.25B	$12.42B
Dividend Yield	N/A	1.79%	2.69%	5.29%
P/E Ratio	207.58	17.67	22.28	24.19
Price / Sales	10.24	743.00	581.86	138.32
Price / Cash	78.03	56.38	42.31	57.88
Price / Book	11.79	3.85	9.84	6.72
Net Income	$99.65M	$75.85M	$3.57B	$337.19M
7 Day Performance	9.00%	-1.69%	-1.15%	0.53%
1 Month Performance	41.29%	22.16%	3.85%	5.10%
1 Year Performance	4.52%	21.78%	27.43%	34.36%

Corcept Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CORT Corcept Therapeutics	4.3866 of 5 stars	$72.65 +2.0%	$88.83 +22.3%	-0.7%	$7.80B	$761.41M	207.58	300	Analyst Forecast Analyst Revision
ANVS Annovis Bio	2.0946 of 5 stars	$2.02 -2.2%	$13.50 +570.0%	-29.1%	$71.37M	N/A	N/A	3
JAZZ Jazz Pharmaceuticals	2.7864 of 5 stars	$237.56 +0.1%	$242.65 +2.1%	+108.8%	$14.91B	$4.44B	N/A	2,890
SUPN Supernus Pharmaceuticals	3.229 of 5 stars	$46.64 -2.4%	$62.17 +33.3%	+38.1%	$2.77B	$718.95M	N/A	580
NKTR Nektar Therapeutics	2.5904 of 5 stars	$65.40 -0.2%	$149.63 +128.8%	+390.2%	$2.22B	$55.23M	N/A	220	Analyst Revision Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CORT) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corcept Therapeutics (CORT) Competitors

CORT vs. ANVS, JAZZ, SUPN, NKTR, and PRGO

How does Corcept Therapeutics compare to Annovis Bio?

Summary

How does Corcept Therapeutics compare to Jazz Pharmaceuticals?

Summary

How does Corcept Therapeutics compare to Supernus Pharmaceuticals?

Summary

How does Corcept Therapeutics compare to Nektar Therapeutics?

Summary

How does Corcept Therapeutics compare to Perrigo?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORT vs. The Competition

Corcept Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corcept Therapeutics (CORT) Competitors

CORT vs. ANVS, JAZZ, SUPN, NKTR, and PRGO

How does Corcept Therapeutics compare to Annovis Bio?

Does the media refer more to ANVS or CORT?

Which has higher earnings & valuation, ANVS or CORT?

Do analysts rate ANVS or CORT?

Is ANVS or CORT more profitable?

Do institutionals & insiders believe in ANVS or CORT?

Which has more risk and volatility, ANVS or CORT?

Summary

How does Corcept Therapeutics compare to Jazz Pharmaceuticals?

Is JAZZ or CORT more profitable?

Do institutionals and insiders believe in JAZZ or CORT?

Do analysts prefer JAZZ or CORT?

Does the media refer more to JAZZ or CORT?

Which has higher valuation and earnings, JAZZ or CORT?

Which has more volatility & risk, JAZZ or CORT?

Summary

How does Corcept Therapeutics compare to Supernus Pharmaceuticals?

Does the media favor SUPN or CORT?

Do institutionals & insiders believe in SUPN or CORT?

Is SUPN or CORT more profitable?

Which has more volatility & risk, SUPN or CORT?

Do analysts rate SUPN or CORT?

Which has higher earnings and valuation, SUPN or CORT?

Summary

How does Corcept Therapeutics compare to Nektar Therapeutics?

Which has better earnings and valuation, NKTR or CORT?

Is NKTR or CORT more profitable?

Do analysts prefer NKTR or CORT?

Do insiders and institutionals believe in NKTR or CORT?

Which has more volatility & risk, NKTR or CORT?

Does the media refer more to NKTR or CORT?

Summary

How does Corcept Therapeutics compare to Perrigo?

Which has more volatility and risk, CORT or PRGO?

Do institutionals and insiders believe in CORT or PRGO?

Is CORT or PRGO more profitable?

Which has preferable earnings and valuation, CORT or PRGO?

Do analysts rate CORT or PRGO?

Does the media refer more to CORT or PRGO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORT vs. The Competition

Corcept Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools